Armata Pharmaceuticals, Inc. (ARMP)
Largest Insider Buys in Sector
ARMP Stock Price History Chart
ARMP Stock Performance
About Armata Pharmaceuticals, Inc.
Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has a partnership agreement with Merck & Co. for developing synthetic bacteriophage candidates to …
Insider Activity of Armata Pharmaceuticals, Inc.
Over the last 12 months, insiders at Armata Pharmaceuticals, Inc. have bought $0 and sold $0 worth of Armata Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Armata Pharmaceuticals, Inc. have bought $30.38M and sold $0 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 5,385,208 shares for transaction amount of $26.93M was made by Innoviva Strategic Opportunities LLC () on 2022‑03‑31.
List of Insider Buy and Sell Transactions, Armata Pharmaceuticals, Inc.
| 2022-03-31 | 5.39M 15.2956% | $5.00 | $26.93M | -26.79% | ||||
| 2022-02-09 | director | 3.61M 12.27% | $5.00 | $18.07M | -21.85% | |||
| 2021-10-29 | 1.21M 5.1858% | $3.30 | $4M | +33.75% | ||||
| 2021-03-17 | 4.29M 12.3568% | $3.25 | $13.93M | -25.41% | ||||
| 2021-01-26 | 1.87M 8.1521% | $3.25 | $6.07M | +13.46% | ||||
| 2020-03-27 | 10 percent owner | 7.72M 66.226% | $2.87 | $22.15M | +7.19% | |||
| 2018-03-22 | director | 181,820 1.2965% | $1.10 | $200,002 | -16.38% | |||
| 2018-03-22 | director | 181,820 1.2965% | $1.10 | $200,002 | -16.38% | |||
| 2017-09-19 | director | 105,015 – | $0 | $0 | +11.11% | |||
| 2017-09-19 | director | 105,015 – | $0 | $0 | +11.11% | |||
| 2017-06-29 | director | 5,757 – | $0 | $0 | +43.42% | |||
| 2017-06-29 | director | 5,757 – | $0 | $0 | +43.42% | |||
| 2016-12-29 | Sale | 10 percent owner | 42,000 0.3166% | $0.45 | $18,900 | -76.14% | ||
| 2016-12-28 | Sale | 10 percent owner | 84,620 0.6272% | $0.47 | $39,771 | -77.66% | ||
| 2016-12-27 | Sale | 10 percent owner | 50,400 0.3723% | $0.51 | $25,704 | -79.31% | ||
| 2016-11-22 | director | 46,666 4.0827% | $7.40 | $345,328 | -81.77% | |||
| 2016-06-21 | director | 15,057 – | $0 | $0 | -70.18% | |||
| 2016-04-08 | director | 171,298 – | $0 | $0 | -61.41% | |||
| 2015-10-06 | director | 10,000 0.1764% | $4.39 | $43,900 | -31.52% | |||
| 2015-10-05 | Chief Executive Officer | 4,200 0.0834% | $4.75 | $19,950 | -28.73% |
Insider Historical Profitability
| Innoviva Strategic Opportunities LLC | 16365969 45.231% | $2.26 | 1 | 0 | <0.0001% | |
| BIOGEN IDEC INC | 10 percent owner | 11704095 32.3469% | $2.26 | 1 | 23 | |
| ELAN CORP PLC | 10 percent owner | 11626282 32.1318% | $2.26 | 1 | 3 | |
| Innoviva, Inc. | director | 10980761 30.3478% | $2.26 | 5 | 0 | +1.43% |
| KIRK RANDAL J | 10 percent owner | 674169 1.8632% | $2.26 | 1 | 3 |
Institutional Investor Ownership
| Bank of America | $2.66M | 1.76 | 636,638 | +0.34% | +$9,141.66 | <0.0001 | |
| The Vanguard Group | $665,494.00 | 0.44 | 159,209 | +9.74% | +$59,067.61 | <0.0001 | |
| Bridgeway Capital Management | $461,397.00 | 0.31 | 110,382 | 0% | +$0 | 0.01 | |
| Edgewood Management | $418,000.00 | 0.28 | 100,000 | 0% | +$0 | <0.01 | |
| Geode Capital Management | $417,648.00 | 0.28 | 99,888 | -1.11% | -$4,703.81 | <0.0001 |